Clinical Trial Update: Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia [Phase 2]

View source ↗

Summary

This clinical trial update reports completion of a Phase 2 trial evaluating ARI-3037MO to reduce triglyceride levels in adults with severe hypertriglyceridemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertriglyceridemia

Drugs mentioned

• ARI-3037MO

Snippet

Sponsor: Arisaph Pharmaceuticals Inc | Conditions: Hypertriglyceridemia | Phase 2 | Status: COMPLETED